Methods of treatment using human antibody molecules for IL-13
AssigneeMedImmune, LLC
InventorsPhillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
Life of this patent
Estimating the term…
Abstract
Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
Claims72
A method of treatment of a disease or disorder selected from the group consisting of asthma, atopic dermatitis, allergic rhinitis, fibrosis and Hodgkin's lymphoma, the method comprising administering a specific binding member to a patient with the disease or disorder, wherein the specific binding member binds interleukin-13 (IL-13) and comprises an antibody antigen-binding site which is composed of a human antibody heavy chain variable region (VH) and a human antibody light chain variable region (VL) comprising a set of complementarity determining regions (CDRs) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein the VH comprises HCDR1, HCDR2 and HCDR3 and the VL comprises LCDR1, LCDR2 and LCDR3, wherein:
- HCDR1 comprises SEQ ID NO:7;
- HCDR2 comprises SEQ ID NO:8;
- HCDR3 comprises SEQ ID NO:9;
- LCDR1 comprises SEQ ID NO:10;
- LCDR2 comprises SEQ ID NO:11;
- and
- LCDR3 comprises SEQ ID NO:12.
A method of treating an interleukin-13 (IL-13) related disorder in a patient comprising administering to the patient an antibody or antibody fragment thereof comprising:
- (a) a set of complementarity determining regions (CDRs) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein HCDR1 comprises SEQ ID NO:7;
- HCDR2 comprises SEQ ID NO:8;
- HCDR3 comprises SEQ ID NO:9;
- LCDR1 comprises SEQ ID NO:10;
- LCDR2 comprises SEQ ID NO:11;
- and
- LCDR3 comprises SEQ ID NO:12;
- or
- (b) a heavy chain variable region (VH) comprising SEQ ID NO:15 and a light chain variable region (VL) comprising SEQ ID NO:16:,
- wherein the IL-13 related disorder is selected from the group consisting of:
- asthma, atopic dermatitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), fibrosis, scleroderma, and Hodgkin's lymphoma.
A method of inhibiting or neutralizing interleukin-13 (IL-13) in a patient comprising administering to the patient an antibody or antibody fragment thereof comprising:
- (a) a set of complementarity determining regions (CDRs) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein
- HCDR1 comprises SEQ ID NO:7;
- HCDR2 comprises SEQ ID NO:8;
- HCDR3 comprises SEQ ID NO:9;
- LCDR1 comprises SEQ ID NO:10;
- LCDR2 comprises SEQ ID NO:11;
- and
- LCDR3 comprises SEQ ID NO:12;
- or
- (b) a heavy chain variable region (VH) comprising SEQ ID NO:15 and a light
- chain variable region (VL) comprising SEQ ID NO:16;
- wherein the patient has a disease or condition selected from the group consisting of:
- asthma, atopic dermatitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), fibrosis, scleroderma, and Hodgkin's lymphoma.
A method of treating asthma in a patient comprising administering to the patient an effective amount of an anti-IL-13 antibody or antibody fragment thereof, wherein the anti-IL-13 antibody or antibody fragment thereof comprises:
- (a) a set of complementarity determining regions (CDRs) HCDR1, HCDR2, HCDR3,
- LCDR1, LCDR2 and LCDR3, wherein
- HCDR1 comprises SEQ ID NO:7;
- HCDR2 comprises SEQ ID NO:8;
- HCDR3 comprises SEQ ID NO:9;
- LCDR1 comprises SEQ ID NO:10;
- LCDR2 comprises SEQ ID NO:11;
- and
- LCDR3 comprises SEQ ID NO:12;
- or
- (b) a heavy chain variable region (VH) comprising SEQ ID NO:15 and a light chain variable region (VL) comprising SEQ ID NO:16.
A method of treating atopic dermatitis in a patient comprising administering to the patient an effective amount of an anti-IL-13 antibody or antibody fragment thereof, wherein the anti-IL-13 antibody or antibody fragment thereof comprises:
- (a) a set of complementarity determining regions (CDRs) HCDR1, HCDR2, HCDR3,
- LCDR1, LCDR2 and LCDR3, wherein
- HCDR1 comprises SEQ ID NO:7;
- HCDR2 comprises SEQ ID NO:8;
- HCDR3 comprises SEQ ID NO:9;
- LCDR1 comprises SEQ ID NO:10;
- LCDR2 comprises SEQ ID NO:11;
- and
- LCDR3 comprises SEQ ID NO:12;
- or
- (b) a heavy chain variable region (VH) comprising SEQ ID NO:15 and a light chain variable region (VL) comprising SEQ ID NO:16.
Dependencies are inferred from the claim text.